• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A high-throughput cellular assay to quantify the p53-degradation activity of E6 from different human papillomavirus types.

作者信息

Gagnon David, Archambault Jacques

机构信息

Laboratory of Molecular Virology, Institut de Recherches Cliniques de Montréal, 110 Pine Avenue West, Montreal, QC, Canada, H2W 1R7.

出版信息

Methods Mol Biol. 2015;1249:111-20. doi: 10.1007/978-1-4939-2013-6_8.

DOI:10.1007/978-1-4939-2013-6_8
PMID:25348301
Abstract

A subset of human papillomaviruses (HPVs), known as the high-risk types, are the causative agents of cervical cancer and other malignancies of the anogenital region and oral mucosa. The capacity of these viruses to induce cancer and to immortalize cells in culture relies in part on a critical function of their E6 oncoprotein, that of promoting the poly-ubiquitination of the cellular tumor suppressor protein p53 and its subsequent degradation by the proteasome. Here, we describe a cellular assay to measure the p53-degradation activity of E6 from different HPV types. This assay is based on a translational fusion of p53 to Renilla luciferase (Rluc-p53) that remains sensitive to degradation by high-risk E6 and whose steady-state levels can be accurately measured in standard luciferase assays. The p53-degradation activity of any E6 protein can be tested and quantified in transiently transfected cells by determining the amount of E6-expression vector required to reduce by half the levels of RLuc-p53 luciferase activity (50 % effective concentration [EC50]). The high-throughput and quantitative nature of this assay makes it particularly useful to compare the p53-degradation activities of E6 from several HPV types in parallel.

摘要

相似文献

1
A high-throughput cellular assay to quantify the p53-degradation activity of E6 from different human papillomavirus types.
Methods Mol Biol. 2015;1249:111-20. doi: 10.1007/978-1-4939-2013-6_8.
2
p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes.p53 降解活性、表达和 29 种人乳头瘤病毒基因型 E6 蛋白的亚细胞定位。
J Virol. 2012 Jan;86(1):94-107. doi: 10.1128/JVI.00751-11. Epub 2011 Oct 19.
3
Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.通过抑制蛋白酶体依赖性降解,“高危”而非“低危”人乳头瘤病毒(HPV)E6蛋白的细胞稳态水平会升高,且这一过程与其p53和E6相关蛋白(E6AP)结合能力无关。
Virology. 2002 Jul 20;299(1):72-87. doi: 10.1006/viro.2002.1502.
4
A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells.一种植物木脂素,3'-O-甲基去甲二氢愈创木酸,可抑制乳头瘤病毒E6蛋白功能,稳定p53蛋白,并诱导宫颈肿瘤细胞凋亡。
Mol Carcinog. 2007 Jul;46(7):564-75. doi: 10.1002/mc.20305.
5
Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification.关于p53降解、永生化、系统发育和流行病学风险分类的19种生殖器人乳头瘤病毒类型的比较分析。
Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1262-7. doi: 10.1158/1055-9965.EPI-05-0778.
6
The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.与HPV 16 E6结合所需的p53结构域与降解结构域是可分离的。
Oncogene. 1995 Feb 2;10(3):457-65.
7
A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.单密码子突变可将人乳头瘤病毒16型(HPV16)E6癌蛋白转化为一种潜在的肿瘤抑制因子,该因子可诱导HPV阳性的人宫颈癌HeLa细胞发生p53依赖性衰老。
Oncogene. 2009 Feb 5;28(5):762-72. doi: 10.1038/onc.2008.422. Epub 2008 Nov 17.
8
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.特定的HIV蛋白酶抑制剂可抑制HPV16 E6降解p53的能力,并在体外选择性杀死依赖E6的宫颈癌细胞。
Antivir Ther. 2006;11(6):813-25.
9
Degradation of p53 by natural variants of the E6 protein of human papillomavirus type 16.HPV16 型 E6 蛋白天然变异体对 p53 的降解。
Oncol Rep. 2013 Apr;29(4):1617-22. doi: 10.3892/or.2013.2281. Epub 2013 Feb 7.
10
The role of TP53 in Cervical carcinogenesis.TP53在宫颈癌发生中的作用。
Hum Mutat. 2003 Mar;21(3):307-12. doi: 10.1002/humu.10178.

引用本文的文献

1
Live cell, image-based high-throughput screen to quantitate p53 stabilization and viability in human papillomavirus positive cancer cells.基于活细胞成像的高通量筛选技术定量检测人乳头瘤病毒阳性癌细胞中 p53 的稳定性和活力。
Virology. 2021 Aug;560:96-109. doi: 10.1016/j.virol.2021.05.006. Epub 2021 May 22.
2
HPV E7 inhibits cell pyroptosis by promoting TRIM21-mediated degradation and ubiquitination of the IFI16 inflammasome.HPV E7 通过促进 TRIM21 介导的 IFI16 炎症小体的降解和泛素化来抑制细胞焦亡。
Int J Biol Sci. 2020 Sep 13;16(15):2924-2937. doi: 10.7150/ijbs.50074. eCollection 2020.
3
A quantitative LumiFluo assay to test inhibitory compounds blocking p53 degradation induced by human papillomavirus oncoprotein E6 in living cells.
一种定量 LumiFluo 测定法,用于检测抑制化合物对人乳头瘤病毒致癌蛋白 E6 诱导的活细胞中 p53 降解的抑制作用。
Sci Rep. 2018 Apr 16;8(1):6020. doi: 10.1038/s41598-018-24470-4.
4
Molecular Probing of the HPV-16 E6 Protein Alpha Helix Binding Groove with Small Molecule Inhibitors.利用小分子抑制剂对人乳头瘤病毒16型E6蛋白α螺旋结合凹槽进行分子探测
PLoS One. 2016 Feb 25;11(2):e0149845. doi: 10.1371/journal.pone.0149845. eCollection 2016.